Is this constipation pill safe for pregnant women? new study investigates
NCT ID NCT04961840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses insurance claims data to see if taking the constipation drug prucalopride during pregnancy is linked to birth defects or other problems for mothers and babies. Researchers will compare pregnant women who took prucalopride, those who took other constipation medicines, and those who took none. The goal is to gather safety information, but because it only looks at past records, it cannot prove whether the drug causes any issues.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the study finds no increased risks, it could provide reassurance that prucalopride is safe to use during pregnancy.
- What could go wrong
- This is an observational study using existing data, not a controlled trial, so it cannot prove cause and effect. Results may be limited by the accuracy of insurance records.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study will include pregnancy women with constipation including those with constipation predominant irritable bowel syndrome.
- Ages
-
18 to 44 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pregnant women aged 18 to 44 years with constipation. * Maternal coverage by health care and prescriptions insurance during eligibility period: a) To study pregnancy outcomes (live births, spontaneous abortions, terminations, or stillbirths): 90 days prior to the LMP until end of pregnancy; and b) to study malformations, perinatal and infant outcomes: 90 days to LMP until 30 days post-delivery. * For infant outcomes, the cohort will be restricted to pregnancies with linked offspring. * For major malformations, only pregnancies with livebirths will be included, since information regarding the pathological results from a pregnancy loss or the indication for termination is rarely recorded. In addition, infants are required to have full insurance coverage from delivery to at least 90 days after the delivery, unless the infant died prior to the end of the 90 days, in which case a shorter eligibility period until death is permitted. * For the analyses of pregnancy losses, the cohort also includes pregnancies ending in spontaneous abortion, terminations, stillbirth and any livebirth (linked or unlinked to a delivery). Exclusion Criteria: * Women with opioids dispensed in the 3 months prior to LMP or during the first trimester (to exclude potential opioid-induced constipation) and women with inflammatory bowel diseases (IBD) (because IBD is a contraindication) * For major malformations, the cohort excludes pregnancies with a chromosomal abnormality based on at least one inpatient or outpatient ICD-9 code for 758.xx,759.81-759.83, or 655.1x within 90 days after delivery in the infant and/or maternal claims. * For major malformations, pregnancies with outpatient exposure to definite teratogens including warfarin, valproate, antineoplastic agents, colchicine, testosterone, radioiodine, isotretinoin, misoprostol, and thalidomide from LMP through LMP plus 90 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Constipation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harvard T.H. Chan School of Public Health
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- How much lidocaine reaches a newborn during an urgent C-Section?
- Could pregnant patients skip clinic visits and monitor their baby from home?
- Can exercise boost the power of abdominal massage for constipation?
- Can a video session get pregnant women to seek more health care?
- Citrulline: a potential key to prolonging pregnancy in pre-eclampsia?
- Can virtual reality coach pregnant women toward healthier habits?